Detalhe da pesquisa
1.
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.
JAMA
; 309(13): 1368-78, 2013 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549582
2.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Hum Vaccin Immunother
; 15(3): 540-548, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30427749
3.
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
Vaccine
; 33(24): 2793-9, 2015 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25913828
4.
Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.
Hum Vaccin Immunother
; 10(12): 3513-6, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25483690
5.
Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine.
Open Forum Infect Dis
; 1(2): ofu071, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25734141
6.
The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.
Vaccine
; 30(9): 1729-36, 2012 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22192849
7.
Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.
Clin Vaccine Immunol
; 19(9): 1509-16, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22837094